Optimus U Corporation | Miami, FL

Research site

(Unclaimed)

Location

3401 NW 7th Street, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Gantenerumab

Donanemab

Iclepertin

ATH-1017

PF-06865571

PTI-125

BI 1569912

PF-05221304

Brexpiprazole

LY3002813

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 44 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. (RSVHR)

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling

RSV Infection

Drug: Placebo

Drug: EDP-938

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting

Alzheimer's Disease

Drug: Remternetug (SC)

Drug: Placebo

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting

Alzheimer's Disease (AD)

Drug: Placebo

Drug: ABBV-916

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt...

Enrolling

Iron Deficiency Anemia

Drug: Iron sucrose

Drug: ferumoxytol

A Study to Test Different Doses of BI 1569912 in People With Depression

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Active, not recruiting

Depressive Disorder, Major

Drug: Placebo matching BI 1569912

Drug: BI 1569912

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intra...

Active, not recruiting

Alzheimers Disease

Drug: Placebo

Drug: RO7126209

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling

Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Drug: Maridebart cafraglutide

Drug: Placebo

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling

Obesity

Drug: Placebo

Drug: Maridebart Cafraglutide

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Drug: Placebo matching survodutide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Drug: Survodutide

Drug: Placebo

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446